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sitivity analysis (PSA) was run with thousand repetitions and a one-way sensitiv-
ity analysis was calculated showing its results in a tornado chart. Results: The 
model showed that everolimus + exemestane results in 0.74 progression free years 
gained with an incremental cost of $18.6 million (MM) resulting in an incremental 
cost-effectiveness ratio (ICER) of $26 MM. The PSA showed that the ICER is within 
the range recommended by WHO (1-3 GDPs per capita) in 71% of cases (Currently 
the GDP per capita in Chile is $10 MM). ConClusions: This analysis showed 
that using everolimus plus exemestane in patients with ER +, HER2- advanced 
breast cancer who have failed on NSAIs is a cost-effective option according to 
WHO recommendations.
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Cost-EffECtivENEss of 2-DosE As04-ADjuvANtED HumAN 
PAPillomAvirus 16/18 vACCiNAtioN sCHEDulE iN slovAkiA
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objeCtives: Slovakia is a country with high incidence and mortality of cervical 
cancer (CC). Despite the improvements in screening (22.9% coverage rate), the CC 
incidence has increased over the past 30 years in Slovakia. Human Papillomavirus 
(HPV) vaccination could help to reduce this CC burden. The objective of this analy-
sis was to assess the cost-effectiveness of adding the AS04-adjuvanted HPV-16/18 
vaccine (AS04V), using a 2-dose administration schedule, to the current CC screen-
ing programme in Slovakia. Methods: A previously published Markov cohort 
model, reproducing the natural history of HPV infection, the impact of screening 
and vaccination, was adapted to the Slovakian settings. Local data on health care 
costs of pre-cancer lesions and CC, obtained from the expert panel, were used. 
Transition probabilities and utilities were estimated from published data. Costs 
were from a health care payer perspective. The incremental CC cases avoided, cost, 
quality-adjusted life-years (QALYs) and resulting cost-effectiveness ratio (ICER) 
of AS04V added to the current CC screening programme versus the current CC 
screening in Slovakia was estimated. The base case assumes a 100% vaccination 
coverage among 12-year-old girls (N= 24,859). A discount rate of 5% was used. 
Univariate sensitivity analyses were carried out on key parameters. Results: 
Compared to screening alone, adding AS04V to the current screening programme 
was estimated to reduce the lifetime CC cases by 328 at an ICER of 11,621 € /
QALY gained. Compared to the official cut-off of 19,320€ /QALY gained, it can be 
considered as cost-effective. Undiscounted analysis shows that AS04V generates 
more QALYs with similar cost versus screening alone (ICER= 5€ /QALY gained). 
Parameters most driving the results were discount rate, vaccine efficacy and dura-
tion of protection. ConClusions: AS04V vaccination of 12-year-old girls in a 
2-dose schedule was estimated to be a cost-effective CC prevention strategy in 
Slovakia.
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A Cost EffECtivENEss ANAlysis of EvErolimus Plus ExEmEstANE 
ComPArED to CHEmotHErAPy AgENts for tHE trEAtmENt of  
Er+ HEr2- mEtAstAstiC BrEAst CANCEr iN tHE uNitED kiNgDom
Polanyi Z.1, Dale P.2, Taylor M.3, Lewis L.3, Glanville J.3, Vieira J.1, Chandiwana D.1
1Novartis Pharmaceuticals UK Limited, Camberley, UK, 2HEOR Solutions, London, UK, 3York 
Health Economics Consortium, York, UK
objeCtives: To evaluate the cost-effectiveness of everolimus plus exemestane 
(EVE+EXE) versus chemotherapy agents [docetaxel (DOC), vinorelbine (VIN), dox-
orubicin (DOX) and capecitabine (CAPE)] for the treatment of hormone receptor 
positive (HR+) HER2 negative (HER2-) advanced or metastatic breast cancer in the 
United Kingdom (UK). Methods: A partitioned survival model was developed to 
compare treatment with EVE+EXE versus DOC, VIN, DOX and CAPE in patients with 
ER+ HER2- metastatic breast cancer over a 10-year time horizon from a UK NHS 
perspective. Progression-free survival and overall survival for EVE+EXE were taken 
from the BOLERO-2 trial. Log-logistic functions were used to extrapolate trial data 
beyond the follow-up period. In the absence of head-to-head evidence comparing 
EVE+EXE versus chemotherapy a naïve chained comparison was conducted with 
the link between EVE+EXE established via tamoxifen using the Bucher method. 
A class effect was assumed for the four chemotherapy agents. Background health 
state and terminal care resource use were derived from NICE Clinical Guideline 81. 
Drug costs were taken from the British National Formulary. Utilities for stable and 
progressive states were obtained from the literature (Lloyd et al. 2006). Results: 
Over a ten year time horizon, EVE+EXE led to a life expectancy of 3.55 years, com-
pared to 1.88 for chemotherapy agents (DOC, VIN, DOX and CAPE). EVE+EXE resulted 
in 2.06 QALYs, compared to 0.95 for chemotherapy agents. Total costs were £48,085 
for EVE+EXE compared to £31,835 vs. DOC, £25,021 vs. VIN, £23,743 vs. DOX and 
£21,851 vs. CAPE. The incremental costs per QALY were £14,550 vs. DOC, £20,653 vs. 
VIN, £21,797 vs. DOX and £23,491 vs. CAPE. Results were most sensitive to changes 
in PFS for chemotherapy and disease related costs. ConClusions: Everolimus in 
combination with exemestane is a cost effective option compared with commonly 
used chemotherapeutic agents (docetaxel, vinorelbine, doxorubicin and capecit-
abine) in UK clinical practice.
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Cost-EffECtivENEss ANAlysis of BEvACizumAB- PAClitAxEl-
CArBoPlAtiN (PC) vErsus PC iN first-liNE tHErAPy of ADvANCED NoN-
smAll CEll luNg CANCEr from PAtiENts’ PErsPECtivE iN viEtNAm
Tran T.T.H., Nguyen T.T.T.
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objeCtives: Bevacizumab in combination with carboplatin/paclitaxel (BCP) was 
approved to be the first-line therapy of advanced NSCLC due to its high clini-
cal efficacy. However, economic effectiveness of BCP has been controversial. This 
study aimed to estimate the cost-effectiveness of BCP versus PC in treatment of 
advanced NSCLC patients from patients’ perspective in Vietnam. Methods: A 
modegib therapy than with SOC for both, laBCC and mBCC patients. ConClusions: 
Vismodegib could provide an effective treatment for this therapeutic area with high 
rate of unmet need. During the adaptation process Delphi-panel surveys seemed 
to be an appropriate method to earn consensus statement to ensure estimation 
and help interpretation.
PCN113
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HumAN PAPillomAvirus-rElAtED CANCErs AND gENitAl WArts iN tHE 
uNitED kiNgDom
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objeCtives: The United Kingdom (UK) runs a successful human papillomavirus 
(HPV) girls vaccination programme. Debate is ongoing on the value of including 
boys in the programme. This study aims at quantifying the potential value associ-
ated with genital warts (GW) and HPV-related cancer prevention in UK males and 
females based on a willingness-to-pay threshold of £20,000 per quality-adjusted 
life-years (QALY) gained, representing the potential value a government places 
on the prevention of these diseases. Methods: A static vaccine steady-state 
(VSS) population model, stratified by age, with a 1-year time horizon, replicated 
the incidence of GW and HPV-related cancers in females (cervical (CC), anal (AC), 
vulvar (VuC), vaginal (VaC), oropharyngeal (OP)) and males (penile (PC), AC and 
OP) pre-vaccination and at VSS. Data were retrieved from UK cancer registries, 
sexually transmitted diseases reports and HPVCentre. Costs and utilities were 
identified from the literature. The VSS vaccine effectiveness for GW and HPV-
related cancers was estimated combining efficacies (AS04-adjuvanted HPV-16/18 
vaccine for cancers; HPV-6/11/16/18 vaccine for GW) weighted by vaccine-types 
(HPV-6/11/16/18) and non-vaccine types (HPV-31/33/35/39/45/51/52/56/58/59) HPV 
distribution. Costs and QALYs were discounted at 1.5%. Per-course vaccine cost-
effective price (vCE-p) was determined by increasing vaccine course price until 
£20,000 per incremental QALY gained at VSS was reached. Sensitivity analyses 
on key variables were performed. Results: The vCE-p in women (men) was: CC 
£790, OP £20 (£57), AC £123 (£77), VaC £37, VuC £58, (PC £40), GW £26 (£27). Total 
value of cancer prevention in women (men) was £1,027 (£173), a proportion of 6: 
1. The value of CC alone is 4.5 times larger than the total value of cancer preven-
tion in men. Sensitivity analyses showed results were robust while influenced by 
potential herd protection. ConClusions: The vCE-p was estimated to be up to 
6 times higher in women than in men due to the higher burden and frequency of 
HPV-related cancers in women.
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Cost-EffECtivENEss of APrEPitANt iN EgyPtiAN PAtiENts rECEiviNg 
HigHly EmEtogENiC tHErAPy from tHE tHirD PArty PAyEr PErsPECtivE
Helal M.1, Elsisi G.2
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objeCtives: to evaluate the cost-effectiveness of aprepitant as add-on ther-
apy to the standard Egyptian regimen in patients receiving highly emetogenic 
therapy. Methods: A decision tree model was developed based on the Egyptian 
clinical practice, and was derived from published sources. This decision analyti-
cal model was constructed to assess the costs and consequences associated with 
aprepitant containing regimen compared with standard therapy for Chemotherapy-
Induced Nausea and Vomiting. The clinical parameters were derived from a ran-
domized trial previously published. The utility of the health states was derived 
using the available published data. Direct medical costs were obtained from the 
third party payer tariff in Egypt. Deterministic sensitivity analyses were conducted. 
All costs (in 2014 EGP) and outcomes were discounted at 3.5% annually. Results: 
The total quality-adjusted life-years (QALYs) of adding aprepitant to the standard 
regimen was estimated to be 0.0082, whereas that of the standard regimen was 
estimated to be 0.0072 (with a net difference of 0.001QALYs). The total costs for 
aprepitant plus standard regimen and standard regimen alone were EGP 414.25 
and EGP 346.62 respectively (with a net difference of EGP 67.63). Thus the incre-
mental cost-effectiveness ratio (ICER) for aprepitant was EGP 66,004/QALY gained. 
The probability of complete protection and incomplete response of both arms 
were found to have the greatest effect on the results. ConClusions:  The present 
study concludes that adding aprepitant to the standard regimen is cost effective 
based on the threshold stated by world health organization (3xGDP/capita) for 
patients with severe vomiting after chemotherapy.
PCN115
Cost EffECtivENEss ANAlysis of EvErolimus + ExEmEstANE for 
PAtiENts WitH ADvANCED BrEAst CANCEr WitH PositivE EstrogEN 
rECEPtor (Er +), HEr2-, rEfrACtory to NoN-stEroiDAl AromAtAsE 
iNHiBitors (NsAis) iN CHilE
Ratto B.1, Torres Ulloa R.2, Cerda Veneros H.2, Anaya P.3
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objeCtives: To evaluate the cost-effectiveness of everolimus plus exemes-
tane in patients with ER+, HER2- advanced breast cancer, who have failed on 
NSAIs. Methods: A Markov model was developed with monthly cycles and a 
time horizon of five years. The model compares progression free survival (PFS) of 
exemestane + everolimus (EVE+EXE) to exemestane monotherapy (EXE). Transition 
probabilities for PFS of EVE+EXE and EXE were based on BOLERO-2 study and calcu-
lated using a fitted Weibull distribution. The R-squared values for the Weibull fits 
were 0.998 and 0.990 for EVE+EXE and EXE alone respectively. The Weibull param-
eters used in the model were: 0.067 and 1.118 for EVE+EXE and 0.191 and 1.006 for 
EXE. Costs considered included drugs and cost of treating neutropenia (other AEs 
are not covered by the National Formulary). The analysis was designed from the 
perspective of the Chilean Public Healthcare. Results are shown in 2014 Chilean 
pesos. A 5% discount rate for costs and efficacies was applied. A probabilistic sen-
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A635
PCN121
Cost-EffECtivENEss ANAlysis of ABirAtEroNE ACEtAtE trEAtmENt 
ComPArED WitH CABACitAxEl iN DomiNiCAN rEPuBliC, iN PAtiENts WitH 
mEtAstAtiC CAstrAtioN-rEsistANt ProstAtE CANCEr tHAt HAvE fAilED 
to CHEmotHErAPy WitH DoCEtAxEl
Obando C.A.1, Desanvicente-Celis Z.1, Gonzalez L.2, Muschett D.1, Gonzalez F.1, Goldberg P.1
1Janssen, Panama, Panama, 2Janssen, Raritan, NJ, USA
objeCtives: To assess the cost-effectiveness of Abiraterone Acetate plus Prednisone 
(A-P) compared with Cabazitaxel plus Prednisone (C-P) in Dominican Republic, in 
patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) that have 
failed to chemotherapy with Docetaxel. Methods: A three-health state cohort sim-
ulation Markov Model (progression-free, post-progression and death) was developed 
based on overall and progression free survival data. The time frame was 10 years. 
The perspective was that of the Public System of Health of Dominican Republic. The 
health outcomes of interest were Quality Adjusted Life Years (QALYs) and Life Years 
(LYs). Efficacy data was taken from clinical trials (COU-AA-301 for A-P and TROPIC 
for C-P). Utilities for health states and negative utilities for adverse events were 
estimated based on quality of life endpoints of the COU-AA-301 trial. The base year 
was 2012. All costs are presented in Dominican currency (Dominican Pesos - RD$). 
Costs and outcomes were discounted at 5%. Probabilistic sensitivity (PSA) analysis 
was performed to evaluate uncertainty surrounding the parameters. Results: 
A-P resulted in 0.79 QALYs and 1.35 LYs, per patient, respectively. C-P resulted in 0.71 
QALYs and 1.28 LYs, per patient, respectively. Mean total costs per patient were: RD$ 
2.204.289 for A-P and RD$ 2.732.365 for C-P. The results of the probabilistic sensitivity 
analysis showed that, when compared with C-Z, A-P was found dominant (associ-
ated with reduced costs and increased QALYs) in the majority of the iterations. A-P 
had a 75% probability of being cost effective, independent of the willingness to pay, 
when compared to C-P. ConClusions: A-P can be considered cost-saving (domi-
nant), when compared with C-P, in patients with Metastatic Castration-Resistant 
Prostate Cancer that have failed to chemotherapy with Docetaxel, from the perspec-
tive of the Public System of Health of Dominican Republic.
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CliNiCAl AND ECoNomiC ANAlysis of EffECtivENEss of EvErolimus iN 
tHE trEAtmENt of Hr+, HEr2- ADvANCED BrEAst CANCEr iN russiA
Krasnova L., Vorobiev P., Holownia M.
Russian Society for Pharmacoeconomics and Outcomes Research, Moscow, Russia
objeCtives: Modern therapeutic approaches in treatment of advanced breast 
cancer can achieve clinically significant regression of symptoms, prolong life and 
improve its quality. Aim of this study was to conduct clinical and economic analysis 
of application of everolimus in the treatment of hormone-receptor-positive (HR+), 
human epidermal growth factor receptor-2-negative (HER2-) advanced breast can-
cer in postmenopausal women. Methods: An epidemiological and pharmaco-
economic evaluation of HR+, HER2- advanced breast cancer in postmenopausal 
women with using a survey of experts from different regions of Russia and mod-
eling method. Calculating the cost of drugs and medical services was conducted 
according to experts and standard of medical care. Filling of a Markov model was 
conducted without using and with using of everolimus in the treatment of the 
patients within 5 years. Calculated indicators were: the impact of the disease on 
budget, the cost of one additional year of life. Results: From 13 regions of Russia 
8 experts refused to provide information on the questionnaire, which may indicate 
the unwillingness to disclose information on epidemiology and tactics of treatment 
of disease. The burden of breast cancer for 5 years without the use of everolimus 
in the treatment regimens of patients with postmenopausal HR+, HER2- advanced 
breast cancer and with using it were: in Moscow 118.668.419€ and 137.596.651€ ; 
St. Petersburg-36.730.318€ and 38.133.492€ ; Republic of Khakassia-18.854.270€ and 
19.812.467€ ; Omsk region-32.428.540€ and 33.603.456€ ; Primorsky Krai-39.176.077€ 
and 40.877.880€ . The use of of everolimus with exemestane in the treatment of 
advanced breast cancer increases by 1.5-2 times life expectancy and its “cost-effec-
tiveness” indicator is 2 times lower comparing to exemestane monotherapy and 
chemotherapy. Sensitivity analysis using the results from 5 regions of Russia showed 
unidirectional comparison. ConClusions: The use of everolimus with exemestane 
is the dominant technology of treatment HR+, HER2- advanced breast cancer in 
postmenopausal patients compared with traditional technology of application of 
chemotherapy drugs or exemestane alone.
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A Cost-EffECtivENEss ANAlysis of Egfr-tk mutAtioN stAtus-guiDED 
1st- AND 2ND-liNE trEAtmENt of stAgE iii/iv NoN-smAll CEll luNg 
CANCEr iN tHE uk
Patel K., Montouchet C., Cheynel J., Ruff L.
Covance Inc., London, UK
objeCtives: Lung cancers are the most common malignant tumours, account-
ing for 1.38 million annual deaths worldwide. Non-small cell lung cancer (NSCLC), 
the predominant tumour subtype, is associated with significant deteriorations in 
both survival and quality of life. Epidermal growth factor receptor tyrosine kinase 
(EGFR-TK) has emerged as a drug therapy target. The National Institute for Health 
and Care Excellence (NICE) recommends erlotinib – an EGFR-TK inhibitor – for 
first-line treatment of NSCLC in EGFR-TK mutation-positive patients, and second-
line treatment in all patients irrespective of EGFR-TK mutations. We developed 
a model to assess the cost-effectiveness of an EGFR-TK mutation status-guided 
treatment strategy for stage III/IV NSCLC, compared with a strategy not depend-
ent on mutational status. Methods: A Markov model was developed from the 
perspective of the UK National Health Service (NHS) over a lifetime horizon. This 
compared a current scenario (in which a cohort of NSCLC patients received dou-
blet chemotherapy at first-line therapy, followed either by erlotinib or docetaxel at 
second-line) to a revised scenario (in which all EGFR-TK mutation-positive patients 
received erlotinib at first-line followed by second-line docetaxel, and all mutation-
negative patients received doublet chemotherapy followed by either docetaxel or 
Markov model was developed to estimate the health outcome (QALY) and total 
treatment costs with Markov cycle of 21 days and lifetime horizon. The effec-
tiveness data was retrieved from the randomized clinical trial ECOG 4599. Direct 
costs, including cost of drugs, administration, medical services, hospital bed day 
and adverse drug reaction management were estimated based on treatment 
guideline of NCCN for NSCLC. Indirect costs, including loss of earnings, cost for 
meal, transportation, accomodation of patients and their caregivers due to treat-
ment, were estimated based on survey of a cohort of 87 patients with NSCLC 
in HCMC Oncology Hospital. Both cost and effectiveness were discounted 3% 
annually. Results: Adding bevacizumab to PC regimen in first-line therapy of 
advanced NSCLC patients resulted in incremental QALY gained of 2.26 month 
compared with PC regimen (7.88 versus 5.62). The total treatment cost with BCP 
was 3 times higher than PC (2,499 millions vs 761.7 millions VND, respectively). 
ICER of BCP versus PC was 768,732,924 VND, which is 3.35 times higher than the 
Willingness-To-Pay of Vietnam in 2013 (229,242,416 VND). A probability sensitivity 
analysis demonstrated the patient’s weight and bevacizumab’s price as the most 
affecting factors to the ICER of BCP vs PC. ConClusions: Conducted analysis 
showed that combination of bevacizumab and PC regimen in first-line therapy 
of NSCLC was not cost-effective compared with PC regimen. Support from the 
manufactures, suppliers and insurance organizations are neccessary to raise its 
economic effectiveness in treatment of advanced NSCLC.
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Cost-EffECtivENEss simulAtioN of ColoNogrAPHy vErsus 
ColoNosCoPy iN gErmANy: is lAxAtivE-frEE ColoNogrAPHy Cost-
EffECtivE?
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objeCtives: Colorectal cancer (CRC) screening using computerised tomographic 
colonography (CTC), also referred to as virtual colonography, has attracted consider-
able attention due to its positive impact on high screening uptake rates, especially 
with a laxative-free preparation before screening. A decision analysis model was 
constructed in order to evaluate the clinical and economic consequences of per-
forming three different screening tests versus a no screening scenario in a popula-
tion at average risk of colorectal cancer in Germany: colonoscopy, conventional 
CT-colonography and laxative-free CT colonography. Methods: A state-transition 
microsimulation was developed for the evaluation of the different screening strate-
gies using TreeAge Pro Healthcare 2014. A hypothetic population of 100,000 German 
asymptomatic adults aged between 50 and 100 years was used for the basis of the 
model. The simulation of the screening strategies was undertaken by assessing the 
number of screening patients diagnosed with CRC on the basis of the sensitivity 
and specificity of each strategy and the related uptake of each screening method. 
Sensitivity analysis will be applied to test the impact of parameter uncertainty on 
model outcomes and recommendations. Results: Initial results of the simula-
tion show that laxative-free colonography was found to be the most costly screen-
ing option, with a total cost of EUR 4,115 per screening patient in the simulation 
model. Colonoscopy was found to be the least costly screening method, with total 
equivalent costs of EUR 2,132. The most effective screening was modeled for laxa-
tive-free colonography. The ICER of laxative-free colonography compared to colonos-
copy was simulated at 5,221 EUR per life year saved. ConClusions: Our simulation 
has shown that using data from new research indicating the possibility of less costly 
use of CTC than previously used for modeling, laxative-free CTC screening has the 
potential to become a cost-effective alternative screening method for CRC due to 
its advantage related to improvements in screening uptake.
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Cost-EffECtivENEss ANAlysis of ABirAtEroNE ACEtAtE trEAtmENt 
ComPArED WitH CABACitAxEl iN CostA riCA, iN PAtiENts WitH 
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objeCtives: To assess the cost-effectiveness of Abiraterone Acetate plus Prednisone 
(A-P) compared with Cabazitaxel plus Prednisone (C-P) in Costa Rica, in patients 
with Metastatic Castration-Resistant Prostate Cancer (mCRPC) that have failed to 
chemotherapy with Docetaxel. Methods: A three-health state cohort simula-
tion Markov Model (progression-free, post-progression and death) was developed 
based on overall and progression free survival data. The time frame was 10 years. 
The perspective was that of the Public System of Health of Costa Rica. The health 
outcomes of interest were Quality Adjusted Life Years (QALYs) and Life Years (LYs). 
Efficacy data was taken from clinical trials (COU-AA-301 for A-P and TROPIC for C-P). 
Utilities for health states and negative utilities for adverse events were estimated 
based on quality of life endpoints of the COU-AA-301 trial. The base year was 2012. 
All costs are presented in Costa Rican currency (Colones - CRC). Costs and outcomes 
were discounted at 5%. Probabilistic sensitivity (PSA) analysis was performed to 
evaluate uncertainty surrounding the parameters. Results: A-P resulted in 0.79 
QALYs and 1.35 LYs, per patient, respectively. C-P resulted in 0.71 QALYs and 1.28 
LYs, per patient, respectively. Mean total costs per patient were: CRC 33.881.184 for 
A-P and CRC 41.981.207 for C-P. The results of the probabilistic sensitivity analysis 
showed that, when compared with C-Z, A-P was found dominant (associated with 
reduced costs and increased QALYs) in the majority of the iterations. A-P had an 
89% probability of being cost effective, independent of the willingness to pay, when 
compared to C-P. ConClusions: A-P can be considered dominant (cost-saving), 
when compared with C-P, in patients with Metastatic Castration-Resistant Prostate 
Cancer that have failed to chemotherapy with Docetaxel, from the perspective of 
the Public System of Health of Costa Rica.
